Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK. Overdijk MB, et al. Among authors: lammerts van bueren jj, van den brakel jh, van de winkel jg. J Immunol. 2011 Sep 15;187(6):3383-90. doi: 10.4049/jimmunol.1003926. Epub 2011 Aug 10. J Immunol. 2011. PMID: 21832160 Free article.
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, van de Winkel JG, Parren PW. Bleeker WK, et al. Among authors: lammerts van bueren jj, van ojik hh, van dijk ma, van de winkel jg. J Immunol. 2004 Oct 1;173(7):4699-707. doi: 10.4049/jimmunol.173.7.4699. J Immunol. 2004. PMID: 15383606
The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Lammerts van Bueren JJ, Bleeker WK, Brännström A, von Euler A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW. Lammerts van Bueren JJ, et al. Among authors: van de winkel jg. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14. doi: 10.1073/pnas.0709477105. Epub 2008 Apr 21. Proc Natl Acad Sci U S A. 2008. PMID: 18427122 Free PMC article. Retracted.
Novel human antibody therapeutics: the age of the Umabs.
Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Ruuls SR, et al. Among authors: lammerts van bueren jj, van de winkel jg. Biotechnol J. 2008 Oct;3(9-10):1157-71. doi: 10.1002/biot.200800110. Biotechnol J. 2008. PMID: 18702090 Free PMC article. Review.
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, Parren PW, van de Winkel JG, Valerius T, Dechant M. Schneider-Merck T, et al. Among authors: van berkel ph, lammerts van bueren jj, van de winkel jg. J Immunol. 2010 Jan 1;184(1):512-20. doi: 10.4049/jimmunol.0900847. Epub 2009 Nov 30. J Immunol. 2010. PMID: 19949082
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.
Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T. Dechant M, et al. Among authors: lammerts van bueren jj, van de winkel jg. Cancer Res. 2008 Jul 1;68(13):4998-5003. doi: 10.1158/0008-5472.CAN-07-6226. Cancer Res. 2008. PMID: 18593896 Free article.
23 results